Familial Mediterranean fever during pregnancy: An independent risk factor for preterm delivery

Ofir, Danielle; Levy, Amalia; Wiznitzer, Arnon; Mazor, Moshe; Sheiner, Eyal

doi:10.1016/j.ejogrb.2008.07.025

Cited by 49 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the addition of the normal healthy control group and the analysis of group 2, which showed similar results (no drawback for colchicine treatment during pregnancy) further support our final conclusions. Finally, the results of the present study are also in accord with those of the relatively older study by Rabinovitch et al (12), and with the very recent one by Ofir et al (13). It should be stressed that the present study is a noninferiority study where we found that treatment with colchicine did not worsen the outcome of pregnancies compared with the nontreated group, and this was clearly shown.…”

Section: Ben-chetrit Et Alsupporting

confidence: 82%

“…Our study included more than twice the number of pregnancies reported in the studies by Rabinovitch et al (12) and Ofir et al (13) and our results are quite similar. The number of early abortions was relatively higher in the untreated group as was also shown by Rabinovitch et al The number of late abortions and congenital malformations was also higher in this group, although not of statistical significance.…”

Section: Discussionsupporting

confidence: 59%

“…However, due to the low number of these cases the authors considered it to be a chance coincidence. In a recent retrospective study, data were collected in delivery rooms, and the outcomes of 239 pregnancies in FMF patients with or without colchicine treatment were compared with the outcomes of pregnancies in healthy women (13). Again, no difference was observed between the 2 groups.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?

Ben‐Chetrit¹,

Ben-Chetrit²,

Berkun³

et al. 2010

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To evaluate the outcome of pregnancies in women with familial Mediterranean fever (FMF) who are taking colchicine, and to reconsider the justification for amniocentesis in these women. Methods. The outcome of 179 pregnancies in a group of women with FMF taking colchicine was compared with the outcome of 197 pregnancies in women with FMF who did not take colchicine during pregnancy and with 312 pregnancies in another cohort of healthy pregnant women of similar age and ethnicity.Results. There was no difference in the 3 groups regarding early abortions, late abortions, or congenital malformations. There was a mild trend towards a better outcome for the colchicine-treated group but these results did not reach statistical significance. Conclusion. Treatment with colchicine during pregnancy in patients with FMF is beneficial in controlling the disease while not affecting the outcome of the pregnancy; therefore there is no justification for recommending amniocentesis in women taking colchicine solely because of this treatment.

show abstract

Section: Ben-chetrit Et Alsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?

Ben‐Chetrit¹,

Ben-Chetrit²,

Berkun³

et al. 2010

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…The course and outcome of pregnancies treated with colchicine was comparable with that of the general population. 4 Furthermore, little is known about the perinatal outcome of patients with FMF. Herein, we report our clinical experience in pregnant women with FMF.…”

mentioning

confidence: 99%

Pregnancy Outcome in Women With Familial Mediterranean Fever: A Retrospective Analysis of 50 Cases With a 10-Year Experience

Yazıcıoğlu

2014

Arch Rheumatol

View full text Add to dashboard Cite

Objectives:Since little is known about perinatal outcome of patients with familial Mediterranean fever (FMF), we report our clinical experience about pregnant women with FMF in this study. Patients and methods: Fifty pregnant women (mean age 29.5 years; range 19 to 39 years) with FMF were enrolled between January 2002 and December 2012. Patient data were collected from computerized database. Clinical characteristics including demographics, pregnancy outcome, maternal and fetal complications during pregnancy or delivery, hypercoagulation disorders and colchicine use were recorded. Labor patterns and perinatal outcomes were assessed. Results: The mean gestational week at delivery was 36.3. Maternal complications were encountered in two patients including hemodialysis associated sepsis and cerebrovascular accident. We did not encounter FMF attacks in the course of pregnancies. A total of 42 patients (84%) were on drug therapy of colchicine. Two congenital anomalies were encountered, one was tanatrophic dysplasia (on colchicine therapy) and the other was an open type neural tube defect (not on colchicine therapy). Patients were also searched for thrombophilias and 15 (30%) had positive test result. The course of the pregnancy was free of venous complications with low molecular weight heparin prophylaxis. Preterm delivery, low birth weight and congenital anomalies were not significantly associated with colchicine therapy. Conclusion: A favorable pregnancy and perinatal outcome may be expected in patients with FMF treated with colchicine. However, close followup with prenatal test and laboratory investigations for maternal and fetal well-being including hypercoagulation disorders are thought to be essential.

show abstract

“…When this occurs, there is the risk of peritonitis which could lead to an eventual abortion. [1,2] Acute intermittent porphyria may cause periodic abdominal pain, and it is one of the hepatic porphyrias in which characteristically no photosensitivity is seen. This is due to mutations in the gene encoding for uroporphyrinogen I synthetase.…”

mentioning

confidence: 99%

Coexistence of Familial Mediterranean Fever and Acute Intermittent Porphyria

2013

View full text Add to dashboard Cite

Familial Mediterranean fever during pregnancy: An independent risk factor for preterm delivery

Cited by 49 publications

References 10 publications

Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?

Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?

Pregnancy Outcome in Women With Familial Mediterranean Fever: A Retrospective Analysis of 50 Cases With a 10-Year Experience

Coexistence of Familial Mediterranean Fever and Acute Intermittent Porphyria

Contact Info

Product

Resources

About